Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $192000.0.

  • Mimedx's Capital Expenditures rose 1228.07% to $192000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 4526.26%. This contributed to the annual value of $1.7 million for FY2024, which is 1529.94% down from last year.
  • Per Mimedx's latest filing, its Capital Expenditures stood at $192000.0 for Q3 2025, which was up 1228.07% from $179000.0 recorded in Q2 2025.
  • Over the past 5 years, Mimedx's Capital Expenditures peaked at $1.9 million during Q1 2021, and registered a low of $105000.0 during Q2 2024.
  • Its 5-year average for Capital Expenditures is $481578.9, with a median of $377000.0 in 2025.
  • In the last 5 years, Mimedx's Capital Expenditures tumbled by 9392.07% in 2022 and then skyrocketed by 43644.07% in 2023.
  • Quarter analysis of 5 years shows Mimedx's Capital Expenditures stood at $325000.0 in 2021, then soared by 105.23% to $667000.0 in 2022, then crashed by 35.98% to $427000.0 in 2023, then plummeted by 38.41% to $263000.0 in 2024, then fell by 27.0% to $192000.0 in 2025.
  • Its Capital Expenditures stands at $192000.0 for Q3 2025, versus $179000.0 for Q2 2025 and $377000.0 for Q1 2025.